Wright G L, Schellhammer P F, Leffell M S, Sieg S M, Brassil B N
Urology. 1982 Apr;19(4):351-5. doi: 10.1016/0090-4295(82)90187-x.
Radioimmunoassay (RIA) kits obtained from commercial sources were evaluated and compared with a standard counterimmunoelectrophoretic (CIE) assay for the measurement of prostatic acid phosphatase (PAP) in serum. None of the radioimmunoassays was found to be more sensitive than the CIE assay in detecting elevated serum PAP. Both immunoassays were somewhat more effective clinically in measuring prostatic specific acid phosphatase than an enzyme colorimetric assay. The results obtained by CIE agreed with the results obtained by RIA in 96 per cent of the tests. The number of positive results in patients with confirmed prostate adenocarcinoma increased with disease progression. The low number of positive tests in localized adenocarcinoma (Stages A and B) suggests that neither the CIE nor any RIA procedure is useful for screening unselected populations for adenocarcinoma of the prostate.
对从商业渠道获得的放射免疫分析（RIA）试剂盒进行了评估，并与标准的对流免疫电泳（CIE）分析法进行比较，以检测血清中前列腺酸性磷酸酶（PAP）的水平。在检测血清PAP升高方面，未发现任何放射免疫分析比CIE分析法更敏感。在临床上，这两种免疫分析法在测量前列腺特异性酸性磷酸酶方面都比酶比色法更有效。CIE获得的结果与RIA在96%的测试中获得的结果一致。确诊为前列腺腺癌的患者中，阳性结果的数量随疾病进展而增加。局限性腺癌（A期和B期）中阳性检测数量较低，这表明CIE和任何RIA程序都不适用于对未经过筛选的人群进行前列腺腺癌筛查。
